Pre Diagnostics
Private Company
Funding information not available
Overview
Pre Diagnostics is an early-stage, private diagnostics company developing a proprietary platform for the early detection of neurodegenerative diseases by analyzing biomarkers inside blood cells (monocytes), rather than in the bloodstream. Its lead program targets Alzheimer's disease (AD) by measuring the dynamic clearance of beta-amyloid, positioning it as a potential tool for pre-symptomatic diagnosis. The company is pre-revenue and research-focused, having recently secured significant non-dilutive funding through a €7.7 million EU Horizon grant to advance its FluiDx-AD project. Its innovative approach differentiates it from conventional plasma-based biomarker tests.
Technology Platform
Intracellular diagnostics platform measuring disease-specific biomarker dynamics (e.g., beta-amyloid clearance) inside monocytes, a type of white blood cell, from a standard blood draw.
Opportunities
Risk Factors
Competitive Landscape
Pre Diagnostics competes in the rapidly evolving Alzheimer's blood test market dominated by companies developing plasma-based assays for biomarkers like p-tau and Aβ42/40. Key competitors include Fujirebio, Roche, Quanterix, and C2N Diagnostics. Pre's differentiation lies in its unique intracellular, functional measurement approach, but it is at an earlier stage of development.